Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Health Catalyst

Health Catalyst Q1 Earnings Call Highlights

Health Catalyst (NASDAQ:HCAT) reported first-quarter 2026 results that topped its own expectations, while management outlined a broad restructuring plan aimed at simplifying the company’s operating model, reducing costs and shifting the business further toward technology-led growth. Chief Executive

Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound

Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound

Check out these three health-tech stocks with prospects of recovery in 2025 after seeing shares decline significantly in 2024.

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022

Upgrades See all analyst ratings upgrades.

12 Health Care Stocks Moving In Friday's Intraday Session

Health Catalyst's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Health Catalyst's (NASDAQ:HCAT) reported sales totaled $68.09 million. Despite a 54.16% increase in earnings, the company posted a loss of $22.46 million.

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap: Health Catalyst Q1 Earnings

Recap: Health Catalyst Q1 Earnings

Health Catalyst (NASDAQ:HCAT) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Health Catalyst beat estimated earnings by 45.45%, reporting an EPS of $-0.06 versus an estimate of $-0.11.

Where Health Catalyst Stands With Analysts

Where Health Catalyst Stands With Analysts

Over the past 3 months, 8 analysts have published their opinion on Health Catalyst (NASDAQ:HCAT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

What 7 Analyst Ratings Have To Say About Health Catalyst

What 7 Analyst Ratings Have To Say About Health Catalyst

Health Catalyst (NASDAQ:HCAT) has observed the following analyst ratings within the last quarter:

Health Catalyst's Return On Capital Employed Overview

Health Catalyst's Return On Capital Employed Overview

Health Catalyst (NASDAQ:HCAT) brought in sales totaling $64.72 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.44%, resulting in a loss of $48.99 million.

Analyst Ratings For Health Catalyst

Analyst Ratings For Health Catalyst

Health Catalyst (NASDAQ:HCAT) has observed the following analyst ratings within the last quarter:

Recap: Health Catalyst Q4 Earnings

Recap: Health Catalyst Q4 Earnings

Health Catalyst (NASDAQ:HCAT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

1

Organisations

Western Digital

Micron Technology

B of A Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play